J&J's Cordis lays off, merges sales staff

With demand for its Cypher heart stent diminishing, Johnson & Johnson medical device subsidiary Cordis will lay off some sales reps and merge its cardiovascular and endovascular units sales forces into one Cordis Vascular group. The total number of employees affected remains undisclosed.

And while J&J spokeswoman Sandra Pound told Reuters the cuts are J&J's way of adapting to the medical device market, Gabelli & Co. analyst Jeff Jonas had a different take. "This is another step to respond to its sales declines and market-share losses," he told Reuters.

- check out the Reuters article

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.